
Sign up to save your podcasts
Or


This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.
By Moira Gunn4.1
2929 ratings
This week on BioTech Nation, Dr. Cory Nicholas, CEO of Neurona Therapeutics, returns for part two. With early results now in from Neurona’s first clinical trial, patients with severe epilepsy are seeing dramatic improvements, including seizure reductions of over 90 percent, and even full remission in some cases. This one-time treatment delivers new brain cells that help calm seizure activity without the side effects of traditional medications or the risks of surgery.

21,968 Listeners

43,850 Listeners

32,012 Listeners

30,699 Listeners

43,592 Listeners

707 Listeners

6,409 Listeners

30,219 Listeners

125 Listeners

320 Listeners

9,904 Listeners

34 Listeners

18 Listeners

48 Listeners

138 Listeners